ITGAM and inflammatory bowel disease: In a DSS-induced IBD model, after three cycles of administration, Muc1 knockout (KO) mice—with deletion confined to the hematopoietic compartment—exhibited a significant increase in CD11b+Ly-6Ct (Gr1+) cells concomitant with a marked reduction in colonic inflammatory lesions.